Curated News
By: NewsRamp Editorial Staff
June 14, 2024
Lisata Therapeutics CEO Encouraged by Progress on Pancreatic Cancer Trial
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Lisata Therapeutics CEO highlights completion of patient enrollment for pancreatic cancer trial, positioning the company ahead in the race for effective cancer treatments.
- The CENDIFOX trial led by Dr. Anup Kasi at The University of Kansas Cancer Center is evaluating the safety and efficacy of certepetide in combination with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers.
- Lisata's Phase 1b/2a CENDIFOX trial aims to collect pre- and post-treatment biopsies of tumors, contributing to the advancement of cancer treatment and bringing hope to patients and their families.
- CEO David Mazzo expresses optimism and notes encouraging progress in the trial, drawing attention to the ongoing efforts and anticipated preliminary results by the end of the year.
Impact - Why it Matters
The completion of patient enrollment for the pancreatic cancer cohorts in Lisata Therapeutics' Phase 1B/2A CENDIFOX trial marks a significant milestone in the evaluation of certepetide's safety and efficacy. This progress brings hope to patients with pancreatic, colon, and appendiceal cancers, and the collection of pre- and post-treatment biopsies could lead to valuable insights for future treatments.
Summary
Lisata Therapeutics Inc. CEO David Mazzo discussed the completion of patient enrollment for the pancreatic cancer cohorts in the company's Phase 1B/2A CENDIFOX trial. The trial, led by Dr. Anup Kasi at The University of Kansas Cancer Center, is evaluating the safety and efficacy of certepetide in combination with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers.
Mazzo highlighted the trial's potential to collect pre- and post-treatment biopsies of tumors and expressed optimism about the progress and enthusiasm surrounding the trial. He anticipates preliminary results by the end of the year.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Lisata Therapeutics CEO Encouraged by Progress on Pancreatic Cancer Trial
